Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ANDRAŠINA Tomáš PÁNEK Jiří HLAVSA Jan BERNARD Vladan VÁLEK Vlastimil

Year of publication 2016
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.7 months in groups A and B, respectively; 3-month and 6-month stent failure was 0% and 6.1% in group A and 6.3% and 25% in group B. The median survival from the initial drainage was 12.3 (6.7- 20.1) and 12.8 (5.7-14.7) months in groups A and B, respectively. Conclusion: The effect of an endoluminal ablation on patients survival was not proven in the prospective randomised clinical study. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. The intervention should be associated with very mild biochemical pancreatitis.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.